

## Index

- ABC score, 126  
 abulia, 303, 311–12  
 ACE-R/III tests, 180  
 acetazolamide, 343  
 acetylcholinesterase, 29  
 acetylcholinesterase inhibitors, 200,  
 210, 289, 462  
   hallucinations and, 464  
 acquired human prion disease, 357–8  
 ACT program, 13  
 actigraphy, 455  
 activities of daily living (ADLs), 218,  
 220  
 actuarial criteria, 233  
 ADDTC criteria, 320–1  
 advanced sleep phase syndrome, 451  
 African-Americans, 45  
 age, 44, *See also* elderly, *See also* early  
 onset  
 agrammatic variant PPA. *See* nonfluent  
 variant PPA (nfvPPA)  
 AHA/ASA statement, 302, 321–2  
 akinesia, 305  
 akinetic mutism, 303  
 alcohol, 47  
 alexia with/without agraphia, 308  
 alpha synuclein. *See* synuclein alpha  
 (SNCA)  
 Alzheimer, Alois, 123, 143  
 Alzheimer's disease, 123, *See also*  
 dementia  
   behavioral symptoms, 127  
   causes and contributions, 1  
   clinical diagnosis, 126–7  
   combination therapy, 417  
   disease-modifying agents, 420–1  
   DLB and, 101, 279, 282  
   drug treatment, 415–17  
   early onset, 57, 198  
   early phase treatment, 421  
   emerging therapies, 419–21  
   epidemiology, 123, 415  
   fMRI studies, 28, 130  
   future directions, 133  
   genetic factors, 124–5  
   GWAS in, 66–7  
   history and neurological  
   examination, 127–8  
   investigational treatments, 132–3  
   laboratory evaluation, 129  
   lvPPA and, 198  
   medical foods, 417–19  
   metabolic agents, 420  
   mouse models, 79–80  
   MRI scans, 22, 129  
   neuroimaging, 129–31  
   neuropathology, 95–9, 125–6  
   neuropsychiatric therapy, 421  
   neuropsychological testing, 128–9  
   neuroregeneration, 421  
   non-mammalian models, 83–5  
   obstructive sleep apnea, 447  
   PET and SPECT studies, 20–1, 130  
   PPA and, 161  
   psychiatric states, 11  
   risk modifiers/susceptibility, 68–9,  
   123–4  
   selective vulnerability, 96  
   susceptibility genes, 62  
   symptomatic treatment, 131–2, 419  
   syndromic diagnosis, 5  
   very old age, 426  
 American football players, 400–1, 403,  
 405  
 amitriptyline, 290  
 amnesia. *See* memory  
 amnesic MCI (aMCI), 218, 226  
   amyloid imaging, 224  
   annual conversion rates, 221  
   apoE4, 225  
   attention and executive dysfunction,  
   222  
   brain imaging, 223  
   case description, 219  
   cognitive impairment, 220  
   criteria for diagnosis, 218  
   CSF/blood biomarkers, 224  
   episodic memory impairment,  
   221–2  
   etiology and neuropathology,  
   225  
   functional independence, 220  
   language impairment, 222  
   management, 225–6  
   neuropsychology, 223  
   prevalence, 221  
   semantic memory, 222  
   visuospatial function, 223  
 amyloid. *See also* beta amyloid  
   cascade, 99  
   imaging, 29–31, 34, 224  
 amyloid precursor protein (APP), 32,  
 63, 124  
   mouse models, 79  
   non-mammalian models, 83  
 amyotrophic lateral sclerosis (ALS), 84,  
 107, 143  
   bvFTD association, 145–6  
   FTD association, 150  
   language disorders, 168  
 anemia, 310  
 aneuploidy, 60  
 angular gyrus syndrome, 307  
 animal models, 77–85  
   advantages of using, 77  
   CADASIL, 339–40  
   mammalian, 78–81  
   non-mammalian, 81–5  
   validity, 78  
 anisotropic diffusion, 26  
 anomia, 157, 159, 179  
 anosmia, 255  
 anterior cerebral artery infarction, 303–6  
 anterocollis, 260  
 anterograde amnesia, 314  
 anti-AGNA (Sox-1) encephalitis, 391  
 anti-AMPA encephalitis, 369, 382–4  
 anti-ANNA-3 encephalitis, 391  
 antibody syndromes, 365  
   cell-surface mediated, 366–85  
   future directions, 392  
   immune response, 392  
   intracellular, 372, 385–92  
   mechanisms, 392  
   patients at high risk, 392  
 anti-CASPR-2 encephalitis, 380  
 Anticholinergic Risk Scale, 429  
 anticholinergics, 251, 439  
 anti-CV2 (CRMP5) encephalitis,  
 389–90  
 antidepressants, 210, 290, 344, 464  
 anti-DPPX encephalitis, 384  
 anti-GABA-AR encephalitis, 384  
 anti-GABA-BR encephalitis, 380–2  
 anti-GAD encephalitis, 388–9  
 anti-Hu (ANNA1) encephalitis, 387–8  
 antihypertensives, 49

- anti-inflammatories, 133  
anti-LGI-1 encephalitis, 379–82  
anti-Ma1/Ma2 encephalitis, 390–1  
anti-mGluR5 encephalitis, 384  
anti-NMDA encephalitis, 367, 369–74  
  demographics and clinical presentation, 374–5  
  diagnostics, 375  
  expanded clinical spectrum, 376  
  false positives, 376  
  psychosis and ketamine, 376–7  
  treatment, 375–6  
  vignette, 377–8  
antioxidants, 48, 133  
anti-PCA-2 encephalitis, 391  
antiplatelets, 343  
antipsychotics, 13, 132, 151, 289, 442  
anti-Tag-1/Contactin-2 encephalitis, 380  
Anton's syndrome, 309  
anxiety, 132, 254, 259, 290  
apathy, 11, 254  
aphasia, 157, 164–5, 311, *See also*  
  primary progressive aphasia (PPA)  
  conduction, 306  
  global, 126, 306, 308  
  logopenic, 126  
  types, 306  
apnea/hypopnea index (AHI), 458  
apoE, 125  
  isoforms, 65  
  models, 79–80  
apoE4, 198, 225, 282, 404  
APP. *See* amyloid precursor protein (APP)  
apraxia, 262, 305–6  
apraxia of speech (AOS), 147, 157, 165, 262  
argyrophilic grain disease (AGD), 107, 148  
aripiprazole, 151  
arousals, 458  
arterial spin labeling (ASL), 22  
aspirin, 343  
atorvastatin, 343  
attentional deficit, 437, 439–40  
autobiographical memory, 183  
autoimmune antibodies, 365  
autoimmune disease, 147, 374, 382, 388  
autoimmune encephalitis, 368  
autonomic features, 2, 255  
autosomal dominant mutations, 61  
Axona, 417–18  
  
Balint's syndrome, 310  
bapineuzumab, 420  
basal ganglia lesions, 311–12  
baseline cognitive function, 437, 440  
basophilic inclusion body disease, 110  
behavioral and psychological symptoms of dementia (BPSD), 9  
behavioral nMCI, 238–41  
behavioral risk factors, 47–8  
behavioral variant FTD (bvFTD), 5, 23, 103–4, 110, 143–6  
  CBD and, 206  
  diagnostic criteria, 145, 263–4  
benzodiazepines, 442, 453  
beta amyloid, 48, 97, 99, 124–5  
  AD therapies, 420  
  CTE, 407  
  investigational treatments, 132  
bilateral hypoperfusion, 151  
Binswanger's disease, 315, 317, 320  
blood biomarkers, 225, 406  
blood pressure, management, 430  
BOLD signal, 27, 29  
borderzone infarction, 310  
Boston Naming Test (BNT), 199  
botulinum toxin, 210  
bovine spongiform encephalopathy (BSE), 357  
boxers, 400, 403  
bradykinesia, 253–4, 262, 265  
brain atrophy. *See also* neuroimaging  
  asymmetrical, 158, 197  
  CADASIL, 336  
  cortical, 125, 151, 204–5  
  focal, 22, 147–8  
  hippocampal, 185  
  peak sites, 158–9  
  regional, 22–5  
brain perfusion measurement, 34  
  CT, 22  
  MRI, 22–5, 34  
  PET and SPECT, 20–2  
brainstem Lewy bodies, 100–1  
Broca's aphasia, 306  
Broca's area, 156, 158  
  
C9ORF72, 84, 108–9, 150–2, 170, 263  
CADASIL, 331  
  animal models, 339–40  
  clinical features, 332  
  cognitive impairment, 333–4  
  differential diagnosis, 342–3  
  epidemiology and vascular risk factors, 331  
  genetics, 340–2  
  ischemic stroke, 332  
  migraine, 332, 342–3  
  MRI studies, 334–8  
  pathology, 338–9  
  psychiatric disturbances, 333  
  treatment and management, 343–4  
CADASIL Scale, 343  
*Caenorhabditis elegans*, 81–4  
Capgras syndrome, 251  
capsular genu lesions, 312  
carbidopa, 152, 210, 251  
cardiovascular risk factors, 45–7  
caregiver stress, 152, 184, 187, 465  
caudate infarction, 311  
cavum septum pellucidum, 404  
CBD. *See* corticobasal degeneration (CBD)  
CBS. *See* corticobasal syndrome (CBS)  
cell surface antibody syndromes, 366–85  
  demographics and clinical presentation, 366–7  
  diagnostics and treatment, 367–9  
central sleep apnea (CSA), 448, 455–6  
CERAD criteria, 99, 126, 128  
cerebellar ataxia, 102  
cerebral microbleeds, 334, 343  
cerebral small vessel disease, 314–18, 331  
  clinico-pathology, 315  
cerebral small vessels, 314  
cerebrospinal fluid (CSF) biomarkers, 224, 288  
  CTE, 406  
  sJCD, 354–6  
cerebrospinal fluid (CSF) studies, 129, 209  
cerebrovascular disease, 19, 301–2, 320, 427  
cerebrovascular reactivity (CVR), 334  
CerefolinNAC, 418  
cholesterol, 46  
cholinergic function, 29  
cholinesterase inhibitors, 131, 151, 251, 289, 344, 415–16, *See also*  
  acetylcholinesterase inhibitors administration, pharmacology and adverse effects, 415  
chromatin, 59  
chronic traumatic encephalopathy (CTE), 107, 400, 409  
  additional risk factors, 404  
  behavioral symptoms, 401  
  cognitive reserve, 408  
  cognitive symptoms, 401  
  concussion and, 401  
  mechanical trauma, 407  
  motor symptoms, 401  
  neurodegeneration risk, 403–4  
  neurodegenerative cascade, 408  
  neuroimaging, 404–6  
  neuropathology, 406–7  
  prevention and treatment, 408–9  
  symptom progression, 401–3  
cingulate atrophy, 23  
circadian rhythm sleep disorders, 450–1  
citalopram, 151

## Index

- Clock Drawing Test, 223  
 clonazepam, 291, 453  
 clozapine, 13, 290  
 codons, 58  
 cognitive domains, 2–3, 220  
 cognitive impairment  
   objective, 220  
   subjective, 220  
 cognitive reserve hypothesis, 124  
 coma, 314  
 combat veterans, 49  
 combination mouse models, 80  
 complex sleep apnea syndrome, 448  
 compulsive behavior, 304  
 computed tomography (CT), 6, 34  
   Alzheimer's disease, 129  
   introduction of, 19  
   regional brain perfusion, 22  
 concussion, 401, 403  
 conduction aphasia, 306  
 confrontation naming, 195, 199, 237  
 Confusion Assessment Method (CAM), 441  
 constipation, 291  
 continuous positive airway pressure (CPAP), 466  
 conversion rates to AD, 221, 234  
 COPD, 310  
 COPE program, 13  
 copy number variants (CNVs), 60, 62  
 cortical atrophy, 125, 151, 204–5  
 cortical blindness, 309  
 cortical Lewy bodies, 100–1  
 cortical thickness, 24, 103, 336  
 corticobasal degeneration (CBD),  
   105–6, 111, 203–4, 246, 261  
   behavioral/psychiatric features, 262  
   bvFTD and, 206  
   CBS correlation, 206–7  
   cognitive features, 262  
   diagnostic criteria, 261  
   epidemiology and genetics, 204  
   lab and biomarker studies, 209  
   motor/extrapyramidal features, 262  
   neuroimaging, 210  
   nfvPPA and, 147, 205–6  
   ocular features, 263  
   pathology, 204  
   sensory features, 262  
   tauopathy, 148  
   therapy, 210  
 corticobasal syndrome (CBS), 102–4,  
   143, 261  
   CBD correlation, 206–7  
   motor deficits, 205  
   naMCI and, 237  
   vignette, 204–5  
 corticobulbar dysfunction, 317  
 corticosteroids, 368, 375, 377  
 costs of care, 44, 415, 425, 436  
 counseling, 225  
 CPAP, 447  
 crenezumab, 420  
 Creutzfeldt–Jakob disease (CJD),  
   111–12, *See also* Jakob–  
   Creutzfeldt disease (JCD)  
   DWI, 25  
   sporadic, 111  
 CTE. *See* chronic traumatic  
   encephalopathy (CTE)  
 cyclophosphamide, 376, 387  
 daytime hypersomnia, 252, 255, 285,  
   459  
 DDD VITAMINS PHS, 4  
 default mode network (DMN), 29  
 delayed sleep phase syndrome (DSPS),  
   451  
 delirium, 429  
   clinical characteristics, 437  
   definitions, 1, 435  
   DSM-IV criteria, 435  
   end-of-life, 439  
   epidemiology, morbidity and costs,  
     435–7  
   etiologies, 438–9  
   future directions, 443  
   history taking, 439–40  
   illegal drugs and, 438  
   in the ICU, 441  
   infections and, 438, 440  
   laboratory assessment, 441  
   management, 442–3  
   medications and, 438–40, 442  
   mental status examination, 440  
   pathophysiology, 439  
   physical examination, 440  
   postoperative, 438  
   risk factors, 437–8  
   scales diagnosing, 441  
 delusions, 251, 254, 286  
 dementia. *See also individual diseases*  
   comprehensive history, 1–3  
   costs, 44  
   information resources, 8  
   initial diagnostic formulation,  
     4–6  
   investigations, 6  
   management strategies, 8  
   neuropsychiatry, 9–14  
   parkinsonism and, 245–9  
   pharmacotherapy, 8  
   physical examination, 3–4  
   prevalence, 44, 425  
   risk factors, 45–9  
   terminology, 1  
   very old age and, 425–30  
 dementia pugilistica, 400  
 dementia with Lewy bodies (DLB), 246,  
   278  
   AD and, 279, 282  
   attention and fluctuation, 284–5  
   autonomic dysfunction, 288  
   autonomic features, 252  
   behavioral symptoms, 250–1, 286–7,  
     290  
   clinical management, 289–91  
   cognitive features, 250, 283, 285–6,  
     289  
   consensus criteria, 279  
   delirium and, 438, 440  
   diagnostic criteria, 249  
   fluctuations in, 253  
   genetics, 292  
   history, 278–9  
   MCI of, 283–4  
   motor features, 251, 287, 290  
   neurochemistry, 291  
   neuroleptic sensitivity, 287  
   neuropathology, 100–2, 279–82, 291  
   ocular features, 252  
   PDD and, 249  
   psychiatric states, 11  
   psychotic symptoms, 289–90  
   sensory features, 252  
   sleep disorders, 251–2, 287, 291, 452  
   syndromic diagnosis, 5  
 depression, 5, 48–9, 132, 254, 259, 286,  
   290  
   and sleep disorders, 463  
   in the elderly, 429  
 dextromethorphan/quinidine, 421  
 diabetes, 46, 388  
 DICE approach, 14  
 diencephalic amnesia, 313  
 diet, 48, 124  
   medical foods, 415, 417–19  
 diffusion tensor imaging (DTI), 25–6,  
   34  
   CADASIL, 337–8  
   CTE, 405  
   longitudinal studies, 33  
   tractography, 337  
 diffusion-weighted imaging (DWI),  
   25–6, 34  
 digit span, 183  
 disinhibition, 206, 238  
 DNA  
   methylation, 58, 70  
   microarrays, 65  
   non-coding, 58  
   regulatory, 58  
 DNA sequence variation, 59–60  
   and disease, 60–2  
 donepezil, 131, 151, 289, 344, 415–16,  
   430  
   dosage, 463

- dopamine agonists, 251  
 dopaminergics, 254  
 doubling time, 426  
 Down's syndrome, 60, 124  
 driver performance, 132, 286  
*Drosophila melanogaster*, 81–4  
 DSM-IV  
   delirium, 435  
   vascular dementia, 321  
 DSM-V, 127  
   MCI guideline, 234  
 DTI. *See* diffusion tensor imaging (DTI)  
 dura mater grafts, 358  
 DWI. *See* diffusion-weighted imaging (DWI)  
 dysarthria, 261, 263  
 dysexecutive nMCI, 235–6, 240–1  
 dysphagia, 128, 261, 263
- E200K mutation, 356  
 early onset  
   AD, 57, 198  
   bvFTD, 145  
   FTD, 143  
 education, 45, 124, 426  
 EFNS guidelines, 386  
 elderly, 83, 425–30  
   delirium and, 435, 439  
   dementia epidemiology, 426  
   dementia prevalence and incidence, 44  
   diagnosis and clinical considerations, 428–30  
   medications and cognitive effects, 429  
   neuropathology, 426–8  
   treatment approaches, 430  
 electrocardiogram (ECG), 455, 459  
 electroencephalography (EEG), 129, 455, 458–9  
   sJCD, 354  
 electromyography (EMG), 456, 459  
 electro-oculogram (EOG), 455, 459  
 emotion processing, 184  
 emotions, recognizing, 256  
 enalapril, 50  
 encephalitis, 367  
   anti-AGNA (Sox-1), 391  
   anti-AMPA, 369, 382–4  
   anti-ANNA-3, 391  
   anti-CASPR-2, 380  
   anti-CV2, 389–90  
   anti-DPPX, 384  
   anti-GABA-AR, 384  
   anti-GABA-BR, 380–2  
   anti-GAD, 388–9  
   anti-Hu (ANNA1), 387–8  
   anti-LGI-1, 379–82  
   anti-Ma1/Ma2, 390–1  
   anti-mGluR5, 384  
   anti-NMDA, 369–78  
   anti-PCA-2, 391  
   anti-Tag-1/Contactin-2, 380  
   autoimmune, 368  
   limbic, 366–7, 378  
 encephalopathies, 1  
 endophenotype, 66–7  
 epigenetic mechanisms, 58, 69–70  
 episodic memory, 2, 183–4  
   impairment, 126, 221–2  
 estrogen, 50  
 estrogen replacement, 133  
 ethnicity, 45, 67  
 excessive daytime sleepiness, 252, 255, 285, 459  
 executive dysfunction, 222, 235–6, 240–1, 257  
   frontal, 259, 318  
 executive functioning, 2–3, 167–8, 306  
 executive-motor presentation, *See* corticobasal syndrome (CBS)  
 expression QTL (eQTL), 69  
 extrapyramidal disorders, 168, 317
- face recognition, 309  
 face validity, 78  
 facial appearance, 258  
 falls, 208–9, 258, 260  
 familial AD, 32, 124–5  
   neuropathology, 99  
 familial CJD (fCJD), 112  
 familial FTD with parkinsonism, 263  
 familial FTL, 149–51, 170  
 familial hemiplegic migraine, 342  
 familial JCD (fJCD), 356  
 family history, 2, 57  
 fatal familial insomnia, 351, 357  
 ferritin levels, 448  
 florbetapir, 30, 130  
 fluctuations, 284–5  
   DLB, 253  
 fluorodeoxyglucose (FDG)-PET, 20, 34, 130, 223  
 fluoxetine, 151  
 focal atrophy, 22, 147–8  
 focal variants of AD, 127  
 focused general medical examination, 4  
 fractional anisotropy (FA), 26  
 frontotemporal dementia (FTD), 143,  
   *See also* behavioral variant FTD (bvFTD)  
   clinical syndromes, 103–5  
   diagnosing, 144–5  
   fMRI, 28  
   FTLD correlation, 110  
   future directions, 152  
   genetics, 21  
   incidence and prevalence, 102  
   mouse models, 80–1  
   neuropathology, 102–11  
   non-mammalian models, 83–5  
   PET and SPECT, 21  
   presymptomatic, 32  
   psychiatric states, 12  
   regional epicenters, 103  
   selective vulnerability, 96  
   tau protein, 31  
   treatment and therapy, 151–2  
 frontotemporal dementia (FTD) with parkinsonism, 246, 263  
   autonomic features, 266  
   behavioral/psychiatric features, 265  
   cognitive features, 264–5  
   diagnostic criteria, 263–4  
   motor/extrapyramidal features, 265–6  
   sleep features, 266  
 frontotemporal lobar degeneration (FTLD), 23–4  
   FTD correlation, 110  
   FUS, 110, 149  
   genetics, 149–51  
   gross anatomical changes, 147  
   history of, 143–4  
   neuroimaging, 151  
   pathology, 104  
   staging system, 104  
   tau, 105–7, 148, 161, 170  
   TDP, 107–9, 149, 161  
   variants, 144  
 functional MRI (fMRI), 27–8, 34, 130  
   presymptomatic imaging, 32  
   resting state, 29  
 FUS protein, 110, 149
- gain-of-function mutations, 61  
 gait impairments, 254, 287  
 galantamine, 131, 151, 289, 416  
   dosage, 463  
 gantenerumab, 420  
 GBA mutation, 292  
 gender differences, 426  
 gender risk factor, 45  
 general neurologic examination, 4  
 genes, 58  
   expression, 58  
   monogenic disorders, 63  
 genetic human prion disease, 356–7  
 genetics, 58–61, *See also* CADASIL  
   AD, 124–5  
   animal models, 77  
   disease-causing mutations, 64–9  
   DLB and PDD, 292  
   FTLD, 149–51  
   neurodegenerative disease, 21, 57–71  
   nfvPPA, 437  
   svPPA, 185

## Index

- genome, 58  
 genome-wide association studies (GWAS), 62, 65–6  
   in AD, 66–7  
 Gerstmann's syndrome, 308  
 Gerstmann–Sträussler–Scheinker syndrome, 357  
 Ginkgo biloba, 133  
 glia, 80  
 glial cytoplasmic inclusions, 102  
 global aphasia, 126, 306, 308  
 glucose metabolism, 20–2  
 grammatical comprehension, 166–7  
 granular osmophilic material (GOM), 338–9, 342–3  
 GRN mutations, 64, 150, 170  
 GWAS. *See* genome-wide association studies (GWAS)
- Hachinski Ischemic Scale, 302, 321  
 haplotype, 61  
 hAPP models  
   mouse, 79  
   non-mammalian, 83  
 head trauma, 49  
 heart failure, 310  
 hemiplegia, 332, 342  
 hereditary dysphasic dementia, 170  
 hippocampal atrophy, 185  
 hippocampal sclerosis, 97, 428  
 Hispanics, 45  
 histone deacetylase, 70  
 histones, 58  
 Hodgkin lymphoma, 384  
 hormone replacement therapy, 50  
 Human Genome Project, 67  
 human growth hormone (hGH), 358  
 human prion disease (hPrD), 350  
   acquired forms, 357–8  
   epidemiology, 350  
   genetic, 356–7  
   neuropathology, 351  
   sporadic, 351–4  
 Huntington's disease (HD), 111, 239  
 huperzine A, 133  
 hyperlipidemia, 46  
 hypersomnia, 463–4  
   daytime, 252, 255, 285, 459  
   of central origin, 451–2  
 hypertension, 46, 50  
 hypoglycemia, 46  
 hypokinesia, 305  
 hypometabolism, 185  
 hypoperfusion, 310–11  
 hyposmia, 255, 282
- iatrogenic JCD, 358  
 ICD-10 criteria for VaD, 321  
 ideogram, 308
- ideomotor apraxia, 305–6  
 idiopathic hypersomnia, 451  
 imitation behavior, 304  
 immunosuppression, 369, 383, 387  
 immunotherapy, 366, 368, 375, 379, 420  
 impairment, definition, 233  
 impulsive behaviors, 304  
 imputation, 68  
 incontinence, 291  
 indels, 59  
 individualization of care, 13  
 infections, delirium and, 440  
 inferolateral artery infarct, 314  
 informant, 1, 453  
 insight, levels of, 286  
 insomnia, 446, 461  
   fatal familial, 351, 357  
 intracellular antibody-associated syndromes, 372, 385–6  
   demographics and clinical presentation, 386  
   diagnostics and treatment, 386–7  
 intravenous immunoglobulin (IVIg), 368, 375, 377  
 invertebrate models. *See* non-mammalian models  
 irregular sleep–wake circadian dysrhythmia, 451  
 ischemic hypoperfusive vascular dementia, 310–11  
 ischemic stroke, 332  
 ischemic vascular disease, 331  
 isotropic diffusion, 26
- Jakob–Creutzfeldt disease (JCD). *See also* Creutzfeldt–Jakob disease (CJD)  
   familial, 356  
   iatrogenic, 358  
   sporadic, 351–6  
   variant, 357–8  
 Japanese, 45, 67  
 ketamine, 376–7  
 Khachaturian criteria, 126  
 knock-in APP models, 79  
 kuru, 350, 357–8
- lacunar infarcts, 334, 336, 338  
 lacunar subcortical VaD, 315, 317  
 lacunes, 315  
 Lambert–Eaton myasthenia, 366, 391  
 language, 3. *See also* aphasia  
   assessment, 156  
   functioning, 2, 45  
   testing, 199–200  
 language disorders, 158  
   AD, 126  
   ALS, 168
- aMCI, 222  
 naMCI, 237–8, 240–1  
 nvfPPA, 156–7, 165–7  
 PSP, 257  
 SvAD, 318  
 L-arginine, 343  
 late-onset AD, 57  
 left-sided svPPA, 147  
 lentiform nucleus infarction, 311  
 levodopa, 152, 210, 250–1, 254, 290  
   MSA-P, 260  
 Lewy bodies (LBs), 100–1, 249, 255, 278–9  
   appearance, 280  
 Lewy body dementia (LBD). *See* dementia with Lewy bodies (DLB)  
 Lewy body disease (LBD), 100–1, 249, 428  
 Lewy neurites (LNs), 100, 249, 278  
 lifestyle risk factors, 47–8  
 limb dystonia, 262  
 limbic encephalitis, 366–7, 378  
 linkage disequilibrium, 60  
 linkage studies, 62, 64–5  
 lipohyalinosis, 315  
 lithium, 133  
 logopenic aphasia, 126  
 logopenic variant PPA (lvPPA), 158, 179, 194  
   clinical features, 194–6  
   diagnostic classification, 196–7  
   histopathology and genetics, 198  
   language difficulties, 164, 166  
   neuroimaging, 197–8  
   neuropsychological and language testing, 198–200  
   sample case, 200  
   treatment, 200  
 longitudinal imaging, 32–3  
 long-term memory consolidation, 221  
 loss-of-function mutations, 61
- magnetic resonance angiography (MRA), 337  
 magnetic resonance imaging (MRI), 6, 19, 34. *See also* functional MRI (fMRI)  
   AD, 129  
   aMCI, 223  
   CADASIL, 334–8  
   CTE, 404–5  
   DWI and DTI and, 25–6  
   longitudinal studies, 33  
   MRS with, 27  
   nvfPPA, 168  
   regional brain perfusion, 22–5  
   sJCD, 353–4  
 magnetic resonance spectroscopy (MRS), 27, 34



- Maintenance of Wakefulness Test (MWT), 459–60  
 mammalian models, 78–81  
 Manhattan plot, 65  
 mania, 305  
 MAPT mutations, 64, 149–50, 170, 204, 263–4  
 Mattis Dementia Rating Scale, 333  
 MCI. *See* mild cognitive impairment (MCI)  
 McKee's four stages of CTE, 402  
 medical foods, 415, 417–19  
 meiotic recombination, 60  
 melatonin, 291, 451, 453, 464  
 memantine, 131, 151, 200, 416, 462  
   administration, pharmacology and adverse effects, 417  
   dosage, 463  
 memory, 3, 183–4  
   autobiographical, 183  
   cortical VaD, 318  
   disturbance, 311  
   episodic, 2, 126, 183–4, 221–2  
   impairments, 195  
   long-term consolidation, 221  
   loss, 127, 309, 311–14  
   semantic, 178, 180–3, 222  
   short-term deficit, 195, 199  
   subjective complaints, 220  
   verbal tests, 128  
   working, 167, 183  
 mental activity, 47  
 metabolic syndrome, 47  
 metaiodobenzylguanidine, 282  
 methylphenidate, 421, 451–2  
 methylprednisolone, 368, 375  
 middle cerebral artery infarction, 306–8  
 migraine, 332, 342–3  
 mild behavioral impairment (MBI), 14  
 mild cognitive impairment (MCI), 250,  
   *See also* vascular MCI (VaMCI),  
   *See also* non-amnesic MCI (naMCI), *See also* amnesic MCI (aMCI)  
   fMRI studies, 28  
   history of, 217–18  
   LDB, 283–4  
   PET and SPECT studies, 21  
   psychiatric states, 11, 14  
 MIND at Home, 14  
 minimal state examination (MMSE), 4, 200, 285, 317  
 minor allele frequency, 59  
 mirabegron, 291  
 missense variants, 59  
 mixed subtype PPA (PPA-M), 160  
 monogenic disorders, 57, 61  
   genetics, 70  
   WES/WGS in, 67–8  
 monozygotic twins, 61  
 Montreal cognitive assessment, 285  
 Morvan's syndrome, 378, 380  
 motor features, 2  
 motor impersistence, 305  
 motor intentional disorder, 305–6  
 motor neuron disease, 104  
 motor perseveration, 305  
 mouse models  
   advantages of, 78  
   Alzheimer's disease, 79–80  
   disadvantages of, 78  
   FTD, 80–1  
 multi-infarct dementia (MID), 302–4  
 multiple sclerosis, 342  
 multiple sleep latency test (MSLT), 452, 459–60  
 multiple system atrophy (MSA), 100, 102  
 multiple system atrophy–parkinsonism (MSA-P), 246, 259  
   autonomic features, 260  
   behavioral/psychiatric features, 259  
   cognitive features, 259  
   diagnostic criteria, 259  
   motor/extrapyramidal features, 260  
   ocular features, 261  
   sensory features, 261  
   sleep disorders, 260  
 multiple system tauopathy with dementia (MST), 107  
 mutations, 59  
   autosomal dominant, 61  
   disease-causing, 64–9  
   loss/gain of function, 61  
   mutism, 126, 303  
   myasthenia, 366, 391  
   myoclonus, 128  
   myo-inositol, 27  
 N-acetyl-aspartate, 27  
 naMCI. *See* non-amnesic MCI (naMCI)  
 narcolepsy, 251, 451  
 neglect syndrome, 307, 309  
 neoplasms, 365–6, 381, 383  
 neuritic plaques (NPs), 97–8, 125  
 neurocognitive disorders, 127  
 neurodegenerative diseases. *See also* dementia  
   genetics, 21, 57–71  
   regional functional and structural changes, 20–5  
   selective vulnerability, 94–5  
 neurofibrillary tangles (NFTs), 31, 48, 97–8, 125  
   CTE, 406  
   quantification, 126  
 neuroimaging, 19–33  
   AD, 129–31  
   amyloids, 29–31  
   CBD and PSP, 210  
   CTE, 404–6  
   FTLD, 151  
   longitudinal, 32–3  
   lvPPA, 197–8  
   neurotransmitter systems, 29  
   nfvPPA, 168–9  
   presymptomatic, 32  
   regional functional and structural changes, 20–5  
   svPPA, 184–5  
   tau, 31–2  
 neuroleptics, 250, 287, 465  
 neuromyotonia, 378  
 neuronal intermediate filament inclusion disease, 110  
 neuropathology, 94  
   AD, 95–9, 125–6  
   amnesic MCI, 225  
   CADASIL, 338–9  
   CBD, 204  
   CTE, 406–7  
   diagnosis, 126  
   DLB, 100–2, 279–82, 291  
   elderly and, 426–8  
   FTD spectrum, 102–11  
   human prion disease, 351  
   MSA, 102  
   nfvPPA, 169–70  
   PPA, 161  
   selective vulnerability, 94–5  
   svPPA, 185  
   neuropsychiatric features, 2, 9  
   neuropsychiatric inventory (NPI), 10, 265, 318  
 neuropsychiatry, 9–14  
 neuropsychological testing, 6, 128–9  
   DLB, 250  
   lvPPA, 198–9  
   svPPA, 180–3  
 neurotransmitter imaging, 29, 34  
 next-generation sequencing (NGS), 62, 64, 67–70  
 nfvPPA. *See* non-fluent variant PPA (nfvPPA)  
 NIA-AA criteria, 99, 127–8, 233  
 NIA-Reagan criteria, 99, 126  
 NINCDS-ARDA criteria, 127  
 NINDS-AIREN criteria, 302, 304, 320  
 NINDS-SPSP criteria, 256  
 nitrendipine, 50  
 NMDA receptor antagonists, 131  
 nocturnal agitation/behavioral dyscontrol, 465

## Index

- non-amnesic MCI (naMCI), 218, 232, 239–40  
 behavioral variant, 238–41  
 dysexecutive, 235–6, 240–1  
 epidemiology, 234–5  
 language variant, 237–8, 240–1  
 terminology and definitions, 232–4  
 visuospatial, 236–7, 240–1
- non-coding DNA, 58
- non-coding RNAs (ncRNAs), 59, 69
- non-coding variants, 61
- non-cognitive domains, 2
- non-fluent variant PPA (nfvPPA), 103–4, 110, 143, 147, 158, 164–5, 170  
 CBD and, 205–6  
 frontal pathology, 169–70  
 genetics, 170  
 language characteristics, 165–7  
 neuroimaging, 168–9  
 non-linguistic deficits, 167–8
- non-mammalian models, 81–5  
 AD and FTD, 83–5  
 advantages and limitations, 81–3  
 therapeutic potential, 85
- nonsense variants, 59
- non-verbal tests, 181
- Notch3*, 331–2, 339–43
- NSAIDs, 50
- obesity, 46
- obstructive sleep apnea (OSA), 260, 446–8, 453, 455–6
- odds ratio, 60
- olanzapine, 151, 289
- old-age dependency ratio, 425
- olfactory dysfunction, 252
- onset of dementia, 2
- Ophelia syndrome, 384
- ophthalmoplegia, 207–8
- orthostatic hypotension, 252, 255, 260
- ovarian teratoma, 374–5, 377
- oxidative stress, 48
- oximetry, overnight, 455
- oxygen saturation, 455
- pain, 256, 261
- PAL test, 222
- palipsychism, 313
- paramedian artery infarction, 313–14
- paraneoplastic neurological syndromes.  
*See* intracellular antibody-associated syndromes
- paraphasia, 157
- parasomnias, 452–3
- Parkinson disease dementia (PDD), 246, 279  
 AD and, 282  
 attention and fluctuation, 285  
 autonomic dysfunction, 288  
 autonomic features, 255  
 behavioral symptoms, 254, 286–7, 290  
 clinical management, 289–91  
 cognitive features, 253, 283, 285–6, 289  
 diagnostic criteria, 253  
 DLB and, 249, 282  
 emotions and, 256  
 genetics, 292  
 motor symptoms, 254–5, 287, 290  
 neuroleptic sensitivity, 287  
 ocular features, 256  
 psychiatric states, 11–12, 254  
 psychotic symptoms, 289–90  
 sensory features, 255  
 sleep disorders, 255, 287, 291
- parkinsonism. *See also* frontotemporal dementia (FTD) with parkinsonism  
 delirium and, 440  
 dementia and, 245–9  
 DLB and, 251  
 MSA and, 102
- Parkinson's disease (PD), 278  
 Braak stages of progression, 281
- peak atrophy sites, 158, 160
- penetrance, 61
- PEPS Scale, 317
- periodic limb movements (PLM), 450, 458
- perseveration, 318  
 motor, 305
- Petersen criteria, 233
- PGRN* mutations, 263, 265
- pharmacotherapy, 13
- phonogram, 308
- phonological deficits, 195–6, 199
- phototherapy, 451
- physical activity, 47, 124, 226, 430
- Pick, Arnold, 143, 178, 194
- Pick bodies, 144, 148
- Pick's disease, 105, 148, 178, 203
- pimavanserin, 290, 421
- Pittsburgh compound B (PIB), 30–1, 130, 151
- polygenic disorders, 57, 62  
 genetics, 70  
 WES/WGS in, 68
- polymorphism, 59
- polysomnography (PSG), 287, 289, 452, 455–9
- positron emission tomography (PET), 20–2  
 amyloids, 29–31, 34  
 CTE, 405  
 FDG-PET, 20, 34, 130, 223  
 ligands, 224  
 neurotransmitters, 29, 34  
 tau, 31–2, 34
- postconcussive syndrome, 401
- posterior cerebral artery infarction, 308–10
- posterior cortical atrophy (PCA), 237
- post-stroke dementia, 301
- post-traumatic stress disorder, 49
- postural deformities, 254
- postural hypotension, 291
- postural instability, 254, 258, 260
- potential support ratio, 425
- PPA. *See* primary progressive aphasia (PPA)
- pravastatin, 50
- praxis, 2–3
- predictive validity, 78
- pre-MCI, 226
- presenilin, 32, 63, 124  
 mouse models, 79
- presymptomatic imaging, 32
- primary dementias, 11–12
- primary progressive aphasia (PPA), 103, 156, 162, *See also* logopenic variant PPA (lvPPA), *See also* semantic variant PPA (svPPA), *See also* non-fluent variant PPA (nfvPPA)  
 asymmetric atrophy, 158  
 classification systems, 160  
 major clinical subtypes, 158–60  
 neuropathology and differential diagnosis, 161  
 patient care, 161  
 progression, 161  
 three criteria for diagnosis, 156–8
- primary sensory features, 2
- prion diseases, 111, 350, *See also* human prion disease (hPrD)  
 biology, 351  
 discovery, 350  
 VGKc antibodies and, 379
- PRNP* gene, 351, 356
- procerus sign, 258
- programmed cell death, 83
- progranulin, 63, 150  
 lvPPA and, 198  
 mouse models, 81  
 non-mammalian models, 84
- progressive non-fluent aphasia (PNFA), 144–5
- progressive supranuclear palsy (PSP), 106–7, 203, 207–8, 246, 256  
 autonomic features, 258  
 behavioral/psychiatric features, 257  
 clinical features, 208–9  
 cognitive features, 257  
 diagnostic criteria, 256–7  
 epidemiology and genetics, 208  
 facial appearance, 258  
 lab and biomarker studies, 209

- motor/extrapyramidal features, 258  
 neuroimaging, 210  
 ocular features, 258  
 pathology, 208  
 sleep disorders, 258  
 tauopathy, 148  
 therapy, 210
- progressive supranuclear palsy  
 syndrome (PSP-S), 102, 104, 143, 207  
 nfvPPA association, 147
- prosody, 165  
 prosopagnosia, 180  
 proteins, abnormal, 19  
 pseudobulbar palsy, 104, 257, 421  
 PSP. *See* progressive supranuclear palsy (PSP)
- psychiatric states, 9–10  
 cognitive trajectories, 11  
 contemporary developments, 13–14  
 frequency and correlates, 10–11  
 management, 12–13  
 measurement, 10  
 primary dementias, 11–12  
 psychometric cutoffs, 233
- psychosis, 421  
 AD and, 132  
 and ketamine, 376–7
- psychosocial risk factors, 48–9  
 pulvinar sign, 358
- quality of life, 446  
 quantitative trait loci (QTL), 66–7, 69  
 Queen Square Brain Bank criteria, 253–4  
 quetiapine, 13, 151, 290, 464
- raloxifene, 50  
 REACH program, 13  
 reading, 3  
 recombination, 60  
 regional brain atrophy, 22–5  
 regulatory DNA, 58  
 REM sleep, 456–8  
 REM sleep–behavior disorder (RBD), 287, 291, 452–3, 456  
 DLB, 251–2  
 MSA-P, 260  
 PDD, 255
- repeat expansions, 62  
 repetition, impaired, 196  
 respiratory disturbance index, 458  
 resting state fMRI, 29  
 resting tremor, 254, 260  
 restless legs syndrome, 448–50  
 review of systems, 3  
 right-sided svPPA, 147  
 rigidity, 208, 258, 262, 265  
 riluzole, 152
- risk variants, 64–9  
 risperidone, 151  
 rituximab, 376  
 rivastigmine, 29, 131, 151, 289, 416  
 dosage, 463  
 RNA  
 interference, 83  
 ncRNAs, 59, 69  
 RT-QUIC test, 355
- salience network, 29  
 Sanger sequencing, 67  
 schizophrenia, 376–7  
 scrapie, 350, 357  
 screening mental status examination, 4  
 secretase inhibitors, 133  
 seizures, 374, 379, 384  
 selective vulnerability, 94–5  
 semantic dementia. *See* semantic variant PPA (svPPA)  
 semantic memory, 178, 181–3, 222  
 semantic variant PPA (svPPA), 103–4, 110, 143, 147, 159, 161, 178  
 clinical diagnosis, 146, 179  
 clinical features, 179–80  
 early history, 178–9  
 genetics, 185  
 language impairments, 164  
 management, 187  
 neuroimaging, 184–5  
 neuropathology, 185  
 neuropsychology, 180–3  
 other memory forms, 183–4  
 prognosis, 186  
 social cognition and emotion, 184
- sentence processing, 166  
 sentence repetition deficits, 199  
 sexual dysfunction, 260  
 shoulder disturbances, 254  
 single infarct dementia, 302  
 single nucleotide polymorphisms (SNPs), 59, 65–6  
 single photon emission computed tomography (SPECT), 20–2, 34, 130  
 DLB and PDD, 288  
 sirolimus, 387  
 sleep architecture, 456  
 sleep diaries/logs, 453  
 sleep disorders, 3, 446. *See also* REM sleep–behavior disorder (RBD)  
 assessment tools, 453–60  
 diagnostic scheme, 460–5  
 DLB, 251–2, 285, 287, 291, 452  
 FTD-P, 266  
 key disorders, 446–53  
 key questions regarding, 453  
 medication effects, 462–4  
 MSA-P, 260
- PDD, 255  
 physical and neurological examination, 454  
 PSP, 258  
 questionnaires and measures used, 454  
 sleep-onset REM (SOREM), 459–60  
 sleep-related leg cramps, 450  
 small cell lung cancer (SCLC), 380–1, 388–9, 391  
 smoking, 48  
 SNCA. *See* synuclein alpha (SNCA)  
 social cognition, 3, 184  
 social functioning, 49, 180  
 sociopathy, 304  
 solanezumab, 133, 420  
 sortilin-related receptor, 125  
 Souvenaid, 418–19  
 speech. *See also* apraxia  
 impairments, 157  
 non-fluent and effortful, 165–6, 205  
 rate of, 165  
 sound errors, 165  
 speech therapy, 200  
 spinocerebellar ataxia, 69  
 spongiform degeneration, 112  
 sporadic fatal insomnia, 351–2  
 sporadic human prion disease, 351–4  
 sporadic JCD (sJCD), 350–1  
 clinical features, 351–3  
 diagnosis, 353–6  
 principal variants, 352  
 SSRIs, 132, 151, 210, 290  
 statins, 50  
 stiff person syndrome, 388  
 STOP–BANG screening tool, 447  
 STR markers, 62, 64  
 stroke, 301–3  
 delirium and, 439–40  
 ischemic, 332  
 subcortical location, 311–14  
 structural variations, 60  
 subcortical ischemic vascular dementia (SIVD), 333, 336, 340  
 subcortical vascular dementia (SVaD), 315–17  
 frontal executive function, attention and speed, 318  
 language, 318  
 memory and visuospatial function, 318  
 neurology, 317–18  
 neuropsychiatry, 318  
 suicide, 254, 401  
 supranuclear gaze palsy, 258  
 surface dyslexia, 180  
 SYDBAT test, 181  
 synaptic loss, 125



## Index

- synuclein alpha (SNCA), 100–2, 278–9  
 abnormalities, 280  
 DLB, 288  
 genetic mutation, 292  
 models, 80  
 neurobiology, 292–3  
 synucleinopathies, 100, 280, 292, 452
- tacrine, 463  
 tandem repeats, 60  
 tau protein, 63, 204  
 AD therapies, 420  
 assays, 129  
 CTE, 406–7  
 FTLN, 105–7, 148, 161, 170  
 imaging, 31–2, 34  
 investigational treatments, 133  
 misprocessing, 99  
 mouse models, 80–1  
 non-mammalian models, 83–4  
 transgenes, 80
- TBI. *See* traumatic brain injury (TBI)  
 T-cells, cytotoxic, 386–7  
 TDP-43  
 CTE, 407  
 FTLN, 107–9, 149, 161  
 mouse models, 81  
 non-mammalian models, 84
- tensor-based morphometry, 33  
 testicular cancer, 390  
 thalamic lesions, 312–14  
 theory-of-mind (ToM) tasks, 184  
 third generation sequencing, 71  
 tissue plasminogen activator, 343  
 tractography, 26, 337  
 transcortical aphasias, 306, 311  
 transcranial magnetic stimulation, 162  
 transcription, 58  
 regulation, 58, 69–70  
 transgenic APP models, 79  
 translation, 58  
 traumatic brain injury (TBI), 49, 400  
 and neurodegeneration, 403–4  
 prevention and treatment, 408–9
- trazodone, 151, 290  
 tremor, 254, 260  
 tricyclic antidepressants, 132  
 tuberthalamic artery infarction,  
 312–13
- Uniform Data Set (UDS), 128  
 unilateral spatial neglect, 307  
 urinary urgency/frequency, 260  
 utilization behavior, 304
- vacuolation, 351  
 variably protease-sensitive  
 prionopathy, 356  
 variant JCD (vJCD), 357–8  
 vascular cognitive impairment (VCI),  
 301–2, 319  
 AHA/ASA statement, 321–2  
 vascular dementia (VaD), 301  
 ADDTC criteria, 320–1  
 anterior cerebral artery infarction,  
 303–6  
 cerebral small vessels, 314–18  
 diagnostic criteria, 301–2  
 DLB and, 286  
 DSM-IV criterias, 321  
 Hachinski Ischemic Scale, 302,  
 321  
 ischemic-hypoperfusive, 310–11  
 middle cerebral artery infarct,  
 306–8  
 NINDS-AIREN criteria, 320  
 posterior cerebral infarct, 308–10  
 psychiatric states, 11  
 single/multiple infarct, 302–4  
 subtypes, 302  
 syndromic diagnosis, 5  
 vascular disease. *See also*  
 cerebrovascular disease  
 delirium and, 439  
 vascular injury, 406  
 vascular MCI (VaMCI), 302, 319,  
 322–3  
 subtypes, 322
- vascular smooth muscle cells (VSMCs),  
 338–9, 342  
 Vayacog™, 419  
 verbal tests, 128, 181  
 vertical gaze, 208  
 vision, 3  
 visual abnormalities, 256, 308  
 visual hallucinations, 250–1, 254, 286,  
 464–5  
 visual illusions, 251  
 visuocognitive disability, 309  
 visuospatial functioning, 2–3, 126, 223,  
 285, 307  
 visuospatial naMCI, 236–7, 240–1  
 visuospatial neglect, 309  
 vitamins, 48, 124, 133  
 voltage-gated potassium channel  
 complex (VGKCC) disorders,  
 378–80  
 von Economo neurons, 103, 148, 169  
 voxel-based morphometry (VBM),  
 23–4
- warfarin, 343  
 Wechsler Logical Memory test, 283  
 Wernicke's aphasia, 126, 306  
 Wernicke's area, 156  
 Western Aphasia Battery (WAB), 199  
 white matter hyperintensities (WMH),  
 315, 334–6, 340  
 white matter tracts, 185  
 whole exome sequencing (WES), 67–9  
 whole genome sequencing (WGS),  
 67–9  
 word-finding deficits, 147, 194, 199,  
 237  
 words, 179  
 comprehension, 180  
 learning techniques, 187  
 tests, 181  
 working memory, 167, 183  
 wrist actigraphy, 455
- zebrafish, 82, 84